Tango Therapeutics, Inc. is announcing the addition of Dr. Michael Palmieri to the leadership team as Head of CMC, where he will be responsible for leading all CMC-related activities for the Company, including process chemistry, drug substance, drug product, analytical, and formulation activities. Dr. Palmieri has more than 20 years of experience, most recently at Alkermes, where he led small molecule CMC activities from the lead optimization phase through to commercialization.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.46 USD | -3.87% | +4.02% | -21.62% |
Apr. 04 | British billionaire Joe Lewis fined $5 million by US judge for insider trading | RE |
Apr. 04 | Multibillionaire Joe Lewis to face US sentencing for insider trading | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.62% | 828M | |
+4.09% | 43.84B | |
+9.45% | 41.68B | |
+45.83% | 41.25B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+1.28% | 12.29B | |
+29.70% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- TNGX Stock
- News Tango Therapeutics, Inc.
- Tango Therapeutics Appoints Dr. Michael Palmieri as Head of CMC